Nonetheless, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL can efficiently eradicate most BCR-ABL-expressing CP-CML cells and as a consequence, have drastically improved the prognosis of CP-CML patients since their clinical introduction two decades ago [104]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.